Dear Madam Gabunia,

 

Thank you for the confirmation. We’ll coordinate with ENSP as per your suggestion.

 

Have a wonderful day,

 

Dmitry Kozenkov Director CauCAR / Caucasus & Central Asia PFIZER Biopharmaceuticals Group www.pfizer.com
PFIZER Export B.V. branch office in Kazakhstan, 100/4 Nazarbayev Ave., 050000, Almaty, Kazakhstan

 

 

 

 

 

Dear Dmitry

Many thanks for your e-mail and follow up. I would be happy to meet ENSP representative on August 9^th at 5 p.m. at the ministry. Let’s coordinate again closer to the meeting.

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Dear Madam Gabunia,

 

I do not mean to bother you with numerous emails.

 

Just wanted to update that should you consider meeting with ENSP beneficial, we’ve obtained there travel schedule and a meeting would be possible Agust 8^th after 6pm or August 9^th after 4 pm (Tbilisi time zone).

 

The meeting possibility lays at your discretion of course.

 

Best regards,

 

Dmitry Kozenkov Director CauCAR / Caucasus & Central Asia PFIZER Biopharmaceuticals Group www.pfizer.com
PFIZER Export B.V. branch office in Kazakhstan, 100/4 Nazarbayev Ave., 050000, Almaty, Kazakhstan

 

 

 

 

 

Dear Madam Gabunia,

 

I do hope this email finds you well.

 

My apologies to interfere into the correspondence. Being aware of the upcoming ENSP (European Network for Smoking and Tobacco prevention) team visit to Georgia for European Accredited Curriculum on Tobacco Treatment (EPACTT) workshop  on August 09, 2019 , I was wondering that it might be a good opportunity to address any of your questions with regard to best EU practices in development of Smoking cessation services to the ENSP team. It might be very useful for further progress on our joint project  “Quit for Free” shared in June 2019  in favor of socially vulnerable population of Georgia. We are partnering with ENSP worldwide and Pfizer’s proposal is based  on the ENSP guidelines for treating of tobacco dependence.

 

Should you be interested in arranging a meeting with ENSP team during August 08-10 2019, please do allow us to share your contacts for ENSP team to arrange the meeting accordingly.

 

Best regards,

 

Dmitry Kozenkov Director CauCAR / Caucasus & Central Asia PFIZER Biopharmaceuticals Group www.pfizer.com
PFIZER Export B.V. branch office in Kazakhstan, 100/4 Nazarbayev Ave., 050000, Almaty, Kazakhstan

 

 

 

 

 

 

Confidential

 

Dear Madam Zhorzholadze,

Dear Madam Adamia,

 

Hope you are doing well!

 

This is to ask your kind support and to find out the status of  Pfizer  offer assessment,  presented earlier in June 2019,  you were working on.

Do you have any preliminary results so far or if  any additional information is required from our side?

 

We will highly appreciate your feedback on the topic if any,

 

Kind regards,

 

 

From: Sultanova, Yuliya
Sent: Thursday, June 13, 2019 5:23 PM
To: 'Ekaterine Adamia' <eadamia@moh.gov.ge>; 'Elene Zhorzholadze' <ezhorzholadze@parliament.ge>
Cc: 'Tamar Gabunia' <tgabunia@moh.gov.ge>; 'Lela Sturua' <lela.sturua@ncdc.ge>
Subject: RE: Information from Pfizer: Pfizer offer modeling data

 

Confidential

 

Dear Madam Zhorzholadze,

Dear Madam Adamia,

 

This is just to clarify  some points of the conditions and terms within the commercial offer shared while the meeting, that  might be useful for your calculations  :

• The product Varenicline (Champix^®) to be supplied in the frame of the Agreement should have not less than 20 months of the rest shelf life at the date of delivery: total Champix shelf life is  36 months. 20 months of shelf life at delivery to Georgia date  is the minimum rest shelf life guaranteed;
• Shipment terms: CIP Tbilisi airport (Incoterm 2010), split shipments are possible: Pfizer is supplying products by air, split shipments are allowed: it means that the proposed annual volume out of total offer volume can be supplied by split shipments, several times per year (2-3 times). Once the payable volume is purchased, Pfizer will be able to send the FOC shipment (either by separate shipment or together with the last payable shipment). 2^nd treatment course (up to 30% of the patients treated) will be provided by a separate written confirmation -request from the Ministry of Healthcare , confirming the number of patients who needs the 2^nd treatment course.
• Agreement currency: US Dollars
• Agreement duration: 3.5 years (2019-2022): as agreed while the meeting , once the in-principal feedback is received from the Ministry and Parliament HC committee   and if it is positive decision, we will request Pfizer HQs on the project delay required for budget allocation form Georgia side. However the consumption was calculated to cover 3.5 year demand.
• Agreement payment terms: 100% prepayment : prepayment is to be proceeded for each of the split shipments separately.
• Agreement delivery terms: 45 days after prepayment arrives to the Pfizer’s bank account:  once the prepayment amount is received to Pfizer bank account , the split shipment is to be initiated.

 

Pfizer is considering partnership solutions with the Georgian clinics for them to propose the Ministry free of charge individual behavioral counselling  support (1+5)  for the socially vulnerable smokers willing to quit and included into the project of nicotine dependence treatment

In addition, Pfizer is ready to educate HCPs providing counselling as well as deliver specially developed educational materials to Patients;

 

Hope it will be helpful,

 

Should you need any further information

Yuliya Sultanova

Commercial manager, Pfizer Innovative Health CauCAR

Mail to: CauCARCom@pfizer.com

Mob. +7 778 747 47 42

 

From: Sultanova, Yuliya
Sent: Wednesday, June 12, 2019 10:15 AM
To: Ekaterine Adamia <eadamia@moh.gov.ge>; Elene Zhorzholadze <ezhorzholadze@parliament.ge>
Cc: Tamar Gabunia <tgabunia@moh.gov.ge>; Lela Sturua <lela.sturua@ncdc.ge>
Subject: Information from Pfizer: Pfizer offer modeling data

 

Dear Madam Zhorzholadze,

Dear Madam Adamia,

 

Thank you for your time spent while the recent meeting with Pfizer.

As it was agreed , let us share with you the demonstrated data background, to support your further assessment of Pfizer offer.

 

Should you need any additional information, like FDA, EU international guidelines, experience of NHS (UK) for organization of SC services , let us know please, we will try to arrange it for you.

Kind regards

Yuliya Sultanova

Commercial manager, Pfizer Innovative Health CauCAR

Mail to: CauCARCom@pfizer.com

Mob. +7 778 747 47 42